with a view to cure possible. The results in this radical group, however, show the major part played by timely operation in colorectal cancer. Most deaths in this group were from liver metastases which were occult at the time of operation: hence adjuvant chemotherapy-possibly by postoperative portal-vein infusion 0-may further improve the results of operation.
Can anything be done for the half who present with ineradicable disease? The only action available at present is to achieve earlier diagnosis. That a long history before diagnosis does not adversely affect outcome only underlines the variability of malignancy between one patient and another. Knowing that a carcinoma is probably present for five years before it is clinically recognised" is a great stimulus to act on any suspicion of carcinoma and to initiate useful investigations. Some patients still report to the outpatient department only after they have complained for months of rectal bleeding or diarrhoea, and several of these have a palpable rectal tumour. Hospital doctors must remember the vital role of sigmoidoscopy in diagnosing rectal neoplasms just out of reach of the finger, the great importance of adenomas of the rectum or sigmoid,"' and that single contrast barium enemas may be misleading (and even double contrast enemas be difficult to interpret) in the proximal colon. ' [3] [4] [5] [6] We therefore compared the effects of the two drugs in patients with myocardial infarction complicated by acute left ventricular failure, and also used both concurrently to determine whether they had a favourable synergistic action.
Patients and methods
Twenty patients were studied. The 17 men and three women had an average age of 63 years (range 46 to 84). All had electrocardiographic evidence of acute myocardial infarction (18 anterior and two inferior) and radiographic evidence of pulmonary oedema. During the study period patients were sedated as necessary with diazepam and given continuous oxygen treatment; one was receiving a lignocaine infusion at a constant rate of 1 5 mg/min. Seventeen patients had not improved on treatment with digoxin and frusemide. One patient was in atrial fibrillation and the rest were in sinus rhythm.
Observations were made in the coronary care unit within 36 hours of admission. Radial artery and right heart pressures and cardiac output were measured as described. The data for salbutamol alone from the first four patients were included in a previous communication. 2 The reasons for the infusions and observations were explained to the patients, but we did not ask for written consent. We believe that this was in the best interests of the patients since our main aim was to plan effective treatment on an individual basis. A more formal approach might have increased both anxiety and risk. The protocol was approved by the ethical committee.
Calculated stroke work index was used as a guide to prognosis.7 Student's t test for paired data was used for statistical comparisons.
Results
The maximum infusion rate of nitroprusside for each patient ranged from 25 to 100 ,ug/min (average 51 25) before an endpoint was reached, while the dose of salbutamol was held constant at 20 ,ug/min.
The haemodynamic effects of the combined drug regimen are summarised in the Final changes in cardiac index and pulmonary artery end-diastolic pressure were similar regardless of which drug was infused first. Nitroprusside accounted for most of the fall in filling pressure in both treatment sequences, whereas nitroprusside and salbutamol contributed almost equally to the augmented cardiac index (fig 2) . BRITISH MEDICAL JOURNAL 16 FEBRUARY 1980 Mean stroke work index for the group was only 14 g M/M2 (range 6-27 g M/M2), also reflecting the severity of left ventricular dysfunction in these patients. Despite this, 10 of the group survived to be discharged from hospital. None died within 24 hours of completion of haemodynamic measurements. 
Discussion
Raised left ventricular filling pressure and reduced cardiac output are the principal haemodynamic consequences of extensive myocardial infarction. If severe they will cause pulmonary oedema and cardiogenic shock. As an isolated complication left ventricular failure often responds rapidly to conventional treatment, but when it is refractory or associated with shock the prognosis is poor and treatment unsatisfactory. We have previously shown that in acute myocardial infarction complicated by severe failure salbutamol infusion at 20 ,ug/min substantially improves cardiac output,2 and our findings in this study confirm this observation. The effect is mediated principally by peripheral arteriolar dilatation due to P2-adrenergic stimulation. Unfortunately left ventricular filling pressure as reflected by pulmonary artery end-diastolic pressure is not affected by salbutamol, and this limits its value as a single therapeutic agent for most patients with a critical haemodynamic state after infarction.
Sodium nitroprusside acts directly on vascular smooth muscle, and unlike salbutamol it reduces both arteriolar and venous tone. The drug has been recommended in the treatment of severe infarction alone,3-6 and in combination with inotropes in refractory heart failure,8 9 because its vascular effects reduce left ventricular filling pressure and produce a variable increase in cardiac output. We expected that sodium nitroprusside and salbutamol would have a useful synergistic action, and our results confirm this.
We were interested to know how far the increase in cardiac output (average 44°%) was due to salbutamol and how far it was due to nitroprusside. The poor clinical condition of our patients precluded prolonged studies with each agent in turn and then combined, but we varied the sequence of treatment. Though we made no attempt to match the groups, the pattern of response was consistent: salbutamol and nitroprusside each accounted for about half the increase in cardiac output irrespective of the order, while nitroprusside accounted for almost all the reduction in filling pressure. Sodium nitroprusside itself has two of the properties we believe to be valuable in severe infarction-namely, arteriolar and venous dilatation. But the drug has important dose-related disadvantages as a single agent, one of which depends on Starling's observation that with reduction of left ventricular filling pressure cardiac output falls. Though patients with severe heart failure tend to have "flat" left ventricular function curves, a decrease in left atrial pressure below about 10 to 15 mm Hg (with reference to sternal angle) adversely influences cardiac output. This effect may occur with nitroprusside sufficiently to overshadow the beneficial effect on output mediated by reduced arteriolar tone.3 5 6 We therefore took special care not to permit pulmonary artery end-diastolic pressure to fall below 15 mm Hg, and at this level we observed a small coincident increase in output.
Sodium nitroprusside as a single agent has other disadvantages. A fall in peripheral resistance which is not matched by a concomitant increase in output will further lower blood pressure. This may affect the distribution of blood flow and is likely to worsen renal function if patients are already hypotensive. We did not always prevent this problem, but the average fall in mean arterial pressure of 13 mm Hg in our patients was considerably less than that recorded in some comparable series studied with nitroprusside alone. 6 We prevented excessive tachycardia and observed an average increase in rate of only three beats/min compared with pretreatment values. With strict adherence to our limited objectives in reducing filling pressure (average 8 mm Hg) we could use a relatively low dose of nitroprusside. Cyanide poisoning from contaminants is a dose-related hazard of nitroprusside treatment. 10 Only five of our patients required more than 50 Ftg/min, and most were at little risk of the hazard since treatment was not usually prolonged.
We believe that combined treatment with salbutamol and nitroprusside, like that with salbutamol alone,2 carries little metabolic cost to the heart. The combined effects on blood pressure and heart rate are small and the changes observed would tend to cancel out as determinants of increased oxygen requirement. Likewise changes in contractility and heart size must be small and would act in opposite directions. Therefore, this treatment should not materially increase infarct size by jeopardising the ischaemic myocardium, whose viability depends on a critical balance between oxygen supply and demand.
Facilities for measuring pressures and flow are not always available in units caring for patients with serious complications of myocardial infarction. On the basis of observations in this and other2 series we believe that a suitable regimen for refractory failure and low cardiac output can be prescribed without invasive monitoring. This comprises salbutamol in a fixed dose of 20 ,ug/min together with a dose of nitroprusside below that which causes any but a trivial increase in heart rate or fall in blood pressure. As with all potent vasoactive compounds, infusion must be controlled with a reliable drip counter or infusion pump.
In such a small group of patients it is difficult to make meaningful comments on the effects of treatment on prognosis.
Chatterjee et a17 reported a hospital mortality with conventional treatment approaching 80% in patients with stroke work indices of 20 g M/M2 or less and left ventricular filling pressure over 15 mm Hg. Eighteen of our 20 patients were in this highrisk group, and nine of these survived. Salbutamol and nitroprusside as combined treatment have an impressive effect on haemodynamics in patients with severe myocardial infarction and refractory left ventricular failure. The possibility that survival may be improved merits further study.
